Table 1.
Baseline Characteristics of the Study Population
| All (N = 118) | No CTRCD (n = 58) | CTRCD (n = 60) | |
|---|---|---|---|
| Age at recruitment, y | 49 (43-58) | 46 (43-53) | 53.5 (45.5-63)a |
| Height, cm | 168 (163-171) | 168 (163-171) | 168 (163-170) |
| Weight, kg | 71 (63-79) | 71 (63-78) | 72.5 (63-81) |
| Body mass index, kg/m2 | 25.0 (22.8-28.0) | 24.4 (22.8-27.0) | 25.4 (22.4-28.6) |
| Systolic blood pressure, mm Hg | 130 (120-140) | 125 (116-135) | 134 (121-144)a |
| Diastolic blood pressure, mm Hg | 80 (75-85) | 80 (70-85) | 80 (75-90) |
| Heart rate, beats/min | 66 (61-73) | 64.5 (58-71) | 68 (63-74.5)a |
| Current smoking | 21 (17.8) | 7 (12.1) | 14 (23.3) |
| Hypertension | 8 (6.8) | 2 (3.5) | 6 (10.0) |
| Diabetes | 2 (1.7) | 2 (3.5) | 0 (0.0) |
| Serum creatinine, mg/dL | 0.74 (0.69-0.81) | 0.72 (0.68-0.80) | 0.75 (0.70-0.81) |
| Blood hemoglobin, g/dL | 13.3 (12.7-13.8) | 13.0 (12.6-13.7) | 13.5 (12.9-13.9)a |
| Epirubicin dose, mg/m2 | 240 (240-360) | 240 (240-360) | 360 (240-400)a |
| Trastuzumab | 27 (22.9) | 9 (15.5) | 18 (30.0) |
| Radiotherapy | 75 (63.6) | 39 (67.2) | 36 (60.0) |
| Left-sided radiation | 27 (22.9) | 16 (27.6) | 11 (18.3) |
| Taxanes | 95 (80.5) | 49 (84.5) | 46 (76.7) |
| Study medication | |||
| Candesartan | 60 (50.8) | 31 (53.4) | 29 (48.3) |
| Metoprolol | 57 (48.3) | 31 (53.4) | 26 (43.3) |
| Follow-up, wk | 101 (82-122) | 99 (72-109) | 105 (89-128)a |
| Circulating biomarkers | |||
| cTnT, ng/L | 3 (3-5) | 3 (3-3) | 3 (3-5)a |
| cTnI, ng/L | 0.8 (0.8-1.4) | 0.8 (0.8-1.2) | 1.2 (0.8-1.8)a |
| NT-proBNP, pg/mL | 5.8 (3.8-9.0) | 6.0 (3.8-8.7) | 5.7 (3.5-9.0) |
| Imaging | |||
| LVEF | 63 (60-66) | 63 (61-65) | 63 (59-66) |
| (n = 88) | (n = 47) | (n = 41) | |
| GLS | 21.8 (20.5-23.0) | 22.4 (20.5-23.1) | 21.1 (20.2-22.7) |
Values are median (Q1-Q3) or n (%). Cumulative incidence of CTRCD using the sex-specific cTnT 99th percentile as the upper reference limit. This table includes the 118 of 120 patients who had at least one valid assessment of CTRCD after initiation of anthracyclines.
cTn = cardiac troponin; CTRCD = cancer therapy–related cardiac dysfunction; GLS = global longitudinal strain; LVEF = left ventricular ejection fraction; NT-proBNP = amino-terminal pro–B-type natriuretic peptide.
a
P < 0.05.